Japan’s M’s Science To Test Herpes Virus For Treating Cancers
This article was originally published in PharmAsia News
Executive Summary
M's Science, a Japanese biotechnology startup, expects to begin U.S. clinical trials by the end of the year on its cancer treatment. The company is relying on a naturally occurring herpes simplex virus to target specific cancer cells in people who already have been infected with the virus. M's Science is testing its treatment on head and neck cancers and expects to begin Phase II trials in 2010. Positive results there could lead the firm to expand the treatment's scope to other cancers. (Click here for more - a subscription may be required
You may also be interested in...
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.